Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Akero Therapeutics, Inc. (AKRO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
21.22+0.28 (+1.34%)
At close: 4:00PM EDT
21.22 0.00 (0.00%)
After hours: 04:01PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close20.94
Open20.86
Bid20.00 x 800
Ask22.71 x 800
Day's Range20.64 - 21.25
52 Week Range17.66 - 34.87
Volume88,840
Avg. Volume182,792
Market Cap739.769M
Beta (5Y Monthly)0.56
PE Ratio (TTM)N/A
EPS (TTM)-2.75
Earnings DateNov 10, 2021 - Nov 15, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est47.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for AKRO

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Akero Therapeutics, Inc.
    Market Digest: CNI, NDAQ, BK, GILD, ISRG, MKTX, NFLX, SWXAs Earnings Roll in, the Economy Rolls on
    Rating
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
  • SmarterAnalyst

    Akero Therapeutics’ NASH Treatment Gets Fast Track Designation; Shares Rise

    Akero Therapeutics (AKRO) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its non-alcoholic steatohepatitis (NASH) treatment, efruxifermin. Following the news, shares of AKRO rose 5.7% in the extended trading session on Tuesday. The stock was trading 9.6% higher, at the time of writing, in early trade on Wednesday. The California-based biotechnology company is engaged in the development of transformational treatments for NASH and other serious met

  • GlobeNewswire

    Akero Therapeutics Receives FDA Fast Track Designation for Efruxifermin (EFX) for the Treatment of NASH

    SOUTH SAN FRANCISCO, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead program investigating efruxifermin (EFX) for the treatment of non-alcoholic steatohepatitis (NASH). The Fast Track designation facilitates the development of new drugs to

  • GlobeNewswire

    Akero Therapeutics to Present at the H.C. Wainwright 5th Annual NASH Investor Conference

    SOUTH SAN FRANCISCO, Calif., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today announced that Tim Rolph, Akero’s Chief Scientific Officer and Co-Founder, will present at the H.C. Wainwright 5th Annual NASH Investor Conference on Tuesday, October 12, 2021 at 12:00 p.m. (ET). A live webcast of the Company presentation will be available through the

Advertisement
Advertisement